Results 91 to 100 of about 114,683,953 (299)
Botulinum Toxin Adverse Events [PDF]
, 2018 Botulinum toxin acts at the neuromuscular junction (motor plaque) blocking the release and effects of acetylcholine (ACh), a neurotransmitter of both the central nervous system (CNS) and the peripheral nervous system (SNP).
Pero, Raffaela +2 more
core +1 more source
Movement Disorders, EarlyView.Abstract Background NKX2‐1–related disorders (NKX2‐1‐RDs) classically present with a triad of neurological, endocrine, and pulmonary manifestations, including benign hereditary chorea. However, in a fraction of patients, NKX2‐1 coding variants are not detected, and variants outside the NKX2‐1 locus have been reported.
Robin Wijngaard +33 more
wiley +1 more source
Neuromodulation: Technology at the Neural Interface, EarlyView., 2021 Abstract Background Refractory chronic migraine (rCM) is a highly disabling condition for which novel safe and effective treatments are needed. Safety and long‐term efficacy of paresthesia‐free high cervical 10 kHz spinal cord stimulation (SCS) were here prospectively evaluated for the treatment of rCM.
Adnan Al‐Kaisy +7 more
wiley +1 more source
A botulinum toxin gyógyászati és kozmetikai felhasználása
, 2015 A botulinum toxin egy rendkívül erős méreg, azonban megfelelő körülmények között, megfelelő dózisban alkalmazva a klinikum számos területén felhasználják.
Bukta, Szilvia
core
Movement Disorders, EarlyView.Abstract Background Bilateral pallidal deep brain stimulation (GPi‐DBS) is effective for dystonia. Long‐term evolution of therapeutic benefit and emergence of parkinsonism have not been systematically characterized. Objectives To assess 15‐year dystonia outcomes and characterize parkinsonism after bilateral GPi‐DBS.
Clément Desjardins +51 more
wiley +1 more source
The role of the host—Neutrophil biology
Periodontology 2000, EarlyView., 2023 Abstract Neutrophilic polymorphonuclear leukocytes (neutrophils) are myeloid cells packed with lysosomal granules (hence also called granulocytes) that contain a formidable antimicrobial arsenal. They are terminally differentiated cells that play a critical role in acute and chronic inflammation, as well as in the resolution of inflammation and wound ...
Iain L. C. Chapple +4 more
wiley +1 more source
Botulinum Toxin and Its Contribution to the Treatment of Masseteric Hypertrophy
Česká Stomatologie a Praktické Zubní Lékařství, 2005 With discovery and use of botulinum toxin masseteric hypertrophy has become treatable in a minimal invasive way. The authors discuss the masseteric hypertrophy as such as well as they describe a technique of clinical application of botulinum toxin in its
R. Jurkovič, P. Macák
doaj
The Effect of Different Doses of Botulinum Toxin on Masseter Muscle in Patients with Bruxism.
Erbil Dental Journal, 2022 Background and Objectives: Botulinum toxin type A is produced by clostridium botulinum. It acts by inhibiting the release of acetylcholine from cholinergic neurons.
Kawa F. Dizaye, Sarezh Jamal Jalal
doaj
Botulinum toxin type-A in the treatment of glabellar lines
, 2009 Leslie Winter1, Jeffrey Spiegel21Department of Otolaryngology, Boston Medical Center, Boston, MA, USA; 2Chief, Division of Facial Plastic Surgery Boston Medical Center Boston, MA, USAAbstract: The current literature and state of the art on use of ...
Leslie Winter, Jeffrey Spiegel
core
Exploring the psychosocial impact of undergoing botulinum toxin treatment
, 2014 In 2012, the American Society for Plastic Surgeons reported that 13 million minimally invasive treatments, such as botulinum toxin injections and dermal fillers, were performed in the US.
Paraskeva, Nicole
core +1 more source